secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001104659-23-044293
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics completes Part A enrollment (33 pts) in Phase 2 DeFianCe study of DKN-01 for colorectal cancer
--------------------------------------------------------------------------------

- Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.
- Part B is planned as a 130-patient randomized controlled trial; primary endpoint is progression-free survival.
- Initial data from the study expected in mid-2023.
- Secondary endpoints include overall response rate, duration of response, and overall survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/0001104659-23-044293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/tm2312449d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-044293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer